Clinical trials
Active, not recruiting trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
1,956 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 2 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 6 |
| 2011 | 3 |
| 2012 | 8 |
| 2013 | 17 |
| 2014 | 22 |
| 2015 | 28 |
| 2016 | 29 |
| 2017 | 59 |
| 2018 | 82 |
| 2019 | 145 |
| 2020 | 159 |
| 2021 | 251 |
| 2022 | 261 |
| 2023 | 292 |
| 2024 | 328 |
| 2025 | 209 |
| 2026 | 48 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 1,956 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 96 |
| Novartis Pharmaceuticals | 82 |
| Hoffmann-La Roche | 74 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 65 |
| Merck Sharp & Dohme LLC | 50 |
| Janssen Research & Development, LLC | 48 |
| AbbVie | 47 |
| Eli Lilly and Company | 34 |
| Bristol-Myers Squibb | 33 |
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | 32 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 118 |
| Breast Neoplasms | 96 |
| Neoplasms | 68 |
| Neoplasm Metastasis | 40 |
| Multiple Myeloma | 38 |
| Prostatic Neoplasms | 36 |
| Colorectal Neoplasms | 35 |
| Ovarian Neoplasms | 33 |
| Melanoma | 32 |
| Recurrence | 32 |
Trials
Showing 1 to 25 of 1,956. Each trial links to its page on Pharma Observatory.
1,856 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.